了解cuproptosis和肝细胞癌的发展之间的关系:针对性治疗的含义
Haixia Zhu1, Yamin Zhao2, Yaxuan Wang1
1Institute of Oncology, Affiliated Tumor Hospital of Nantong University & Nantong Tumor Hospital, Nantong, China.
Frontiers in immunology
|March 27, 2025
概括
肝细胞癌 (HCC) 的进展与铜代谢有关. 准铜诱导的细胞死亡为肝癌提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 代谢学 代谢学 代谢学
背景情况:
- 肝细胞癌 (HCC) 是一个主要的全球健康问题,在发展中国家的发病率很高.
- 目前的HCC治疗因高恶性瘤,转移和耐药性而面临挑战,需要更深入的病原遗传学理解.
研究的目的:
- 审查铜亡在肝细胞癌 (HCC) 发展和进展中的作用.
- 阐明将铜失调与HCC病变发生联系起来的分子机制.
- 确定铜亡作为HCC的潜在治疗点.
主要方法:
- 关于铜代谢和HCC的最新研究的综合文献综述.
- 对研究铜诱导细胞死亡途径的实验数据的分析.
- 检查铜介导氧化应激,热和铁的分子机制.
主要成果:
- 不调节的铜代谢有助于HCC的发展和进展.
- 过量的铜会诱导氧化应激,热和铁,促进瘤发生.
- 铜亡途径与HCC病变发生有着复杂的关系.
结论:
- 铜代谢在肝细胞癌中起着至关重要的作用.
- 铜诱导的细胞死亡机制是HCC进展的关键驱动因素.
- 向铜亡是一种有希望的治疗途径,可以改善HCC治疗结果.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K


